Zomedica Corp., a veterinary health company, focuses on the unmet needs of clinical veterinarians by developing products for companion animals. The company offers diagnostic products comprising TRUFORMA Bulk Acoustic Wave point of care diagnostic platform; TRUVIEW, a digital cystoscopy platform that offers automated slide preparation within the instrument; and VetGuardian, a zero-touch vital signs remote monitoring system. It also provides therapeutic products, including PulseVet electrohydraulic shockwave therapy platform; and Assisi Loop line of products, including the Assisi Loop, Assisi Loop Lounge, and DentaLoop devices that treat pain and inflammation through delivery of targeted pulsed electromagnetic field focused energy. The company has collaboration agreements with Celsee, Inc. for the development and commercialization of liquid biopsy assays and related consumables for the detection of cancer in companion animals; and Seraph Biosciences, Inc. for the development of a novel pathogen detection system. The company was formerly known as Zomedica Pharmaceuticals Corp. and changed its name to Zomedica Corp. in October 2020. Zomedica Corp. is headquartered in Ann Arbor, Michigan.
Frequently asked questions
What sector does Zomedica Corp (ZOM) operate in?
Zomedica Corp belongs to the Healthcare sector and operates in the Medical Devices industry.
What is Zomedica Corp (ZOM) Earnings Per Share (EPS)?
The trailing EPS is -$0.06, and the forward EPS is -$0.03.
What is Zomedica Corp (ZOM) EBITDA?
Zomedica Corp EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -64.55 million.
Does Zomedica Corp (ZOM) pay dividends?
No. Zomedica Corp does not pay a dividend.
When is Zomedica Corp (ZOM) next earnings report?
Zomedica Corp is expected to release its next earnings report on June 30, 2025.
What is Zomedica Corp (ZOM) beta (volatility) score?
Zomedica Corp has a beta of 1.156, meaning its volatility is roughly in line with the market.
